DrugPatentWatch Database Preview
FOLOTYN Drug Profile
or, see our see our flat-rate plans
When do Folotyn patents expire, and what generic alternatives are available?
This drug has forty-two patent family members in twenty-one countries.
The generic ingredient in FOLOTYN is pralatrexate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pralatrexate profile page.
Summary for FOLOTYN
| International Patents: | 42 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 49 |
| Clinical Trials: | 18 |
| Patent Applications: | 851 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for FOLOTYN |
| DailyMed Link: | FOLOTYN at DailyMed |
Pharmacology for FOLOTYN
| Drug Class | Folate Analog Metabolic Inhibitor |
Synonyms for FOLOTYN
| (2S)-2-((4-((1RS)-1-((2,4-Diaminopteridin-6-yl)methyl)but-3-ynyl)benzoyl)amino)pentanedioic acid |
| (2S)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}amino)pentanedioic acid |
| (2S)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]phenyl}formamido)pentanedioic acid |
| (2S)-2-(4-(1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzamido)pentanedioic acid |
| (2S)-2-[[4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl]amino]pentanedioic acid |
| (2S)-2-[[4-[1-[(2,4-diaminopteridin-6-yl)methyl]but-3-ynyl]benzoyl]amino]pentanedioic acid |
| (4-(1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzoyl)-L-glutamic acid |
| 10-Propargyl-10-deazaaminopterin |
| 146464-95-1 |
| 2667AH |
| 3B1-001405 |
| 464P951 |
| AB00443251_04 |
| AB00443251-02 |
| AB0095450 |
| AB2000123 |
| ABP000543 |
| AC-28388 |
| AC1L3WHA |
| AK162224 |
| AKOS015966891 |
| AM84423 |
| AN-6340 |
| API0005288 |
| AX8248565 |
| BCPP000101 |
| CAS-146464-95-1 |
| CHEBI:71223 |
| CHEMBL1201746 |
| CS-0504 |
| D02LWU |
| D05589 |
| DB06813 |
| DSSTox_CID_28504 |
| DSSTox_GSID_48578 |
| DSSTox_RID_82776 |
| DTXSID3048578 |
| Folotyn (TN) |
| FT-0673988 |
| GTPL6840 |
| HE069856 |
| HE250885 |
| HSDB 7786 |
| HY-10446 |
| J-008227 |
| KS-00001CSH |
| L-Glutamic acid, N-(4-(1-((2,4-diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)- |
| MolPort-009-679-397 |
| N-(4-(1-((2,4-Diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid |
| N-[4-[1-[(2,4-Diamino-6-pteridinyl)methyl]-3-butyn-1-yl]benzoyl]-L-glutamic Acid |
| N-[4-[1-[(2,4-Diamino-6-pteridinyl)methyl]-3-butynyl]benzoyl]-L-glutamic Acid |
| N-{4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}-L-glutamic acid |
| NCGC00242596-01 |
| NSC-754230 |
| NSC754230 |
| OGSBUKJUDHAQEA-WMCAAGNKSA-N |
| Pralatrexate |
| Pralatrexate (JAN/USAN/INN) |
| Pralatrexate [USAN:INN] |
| Pralatrexate(Folotyn) |
| Pralatrexate(Folotyn)/ |
| pralatrexato |
| pralatrexatum |
| QC-3214 |
| s1497 |
| SC-21536 |
| SCHEMBL15075302 |
| SCHEMBL21633 |
| SR-01000941578 |
| SR-01000941578-1 |
| ST24049028 |
| Tox21_112906 |
US Patents and Regulatory Information for FOLOTYN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allos | FOLOTYN | pralatrexate | SOLUTION;INTRAVENOUS | 022468-001 | Sep 24, 2009 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Allos | FOLOTYN | pralatrexate | SOLUTION;INTRAVENOUS | 022468-002 | Sep 24, 2009 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Allos | FOLOTYN | pralatrexate | SOLUTION;INTRAVENOUS | 022468-001 | Sep 24, 2009 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Allos | FOLOTYN | pralatrexate | SOLUTION;INTRAVENOUS | 022468-001 | Sep 24, 2009 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
or, see our see our flat-rate plans
Paragraph IV (Patent) Challenges for FOLOTYN
| Drugname | Dosage | Strength | RLD | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 20 mg/mL and 40 mg/2 mL | ➤ Subscribe | 2013-09-24 |
Non-Orange Book US Patents for FOLOTYN
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,168,404 | Methods to treat cancer with 10-propargyl-10-deazaaminopterin and methods for assessing cancer for increased sensitivity to 10-propargyl-10-deazaaminopterin | ➤ Sign Up |
| 6,323,205 | Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors | ➤ Sign Up |
| 8,263,354 | Methods for assessing cancer for increased sensitivity to 10-propargyl-10-deazaaminopterin | ➤ Sign Up |
| 7,939,530 | Treatment of lymphoma using 10-propargyl-10-deazaaminopterin and gemcitabine | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
or, see our see our flat-rate plans
International Patents for FOLOTYN
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Spain | 2313737 | ➤ Sign Up |
| Portugal | 944389 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 2005117892 | ➤ Sign Up |
| South Korea | 101189692 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
